National Comprehensive Cancer Network

NCCN Compendium®
About the NCCN Compendium®
NCCN Compendium™ Chapters By Disease
Transparency: Process and Recommendations
No Longer Recommended Uses
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements

NCCN Guidelines® & Clinical Resources

NCCN Breast Cancer Guidelines Update

Clinicians

Interactive Learning

Download Podcast

Listen to MP3

Podcast Evaluation


Go back to previous page

 

 

     
 

NCCN Breast Cancer Guidelines Update

Download Podcast

Listen to MP3

Podcast Evaluation

A presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 16, 2007

Presenters

Beryl McCormick, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

John H. Ward, MD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Faculty Disclosure Statements

Beryl McCormick, MD

Dr. McCormick has disclosed that she has no financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in her presentation or who may financially support the educational activity.  Dr. McCormick has indicated that her presentation will not include discussion of investigational or unlabeled uses of a product.

John H. Ward, MD

Dr. Ward has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity.  He has served as a paid consultant for Myriad Genetics, Inc. and the National Cancer Institute.  Dr. Ward has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.

Program Overview

This presentation will focus on the rationale behind the latest changes to the NCCN Breast Cancer Guidelines, including the issues surrounding the use of MRI in the workup of patients with breast cancer.  Guidelines for HER2 testing and the use of trastuzumab will also be discussed.

Educational Objectives

Following this activity, participants should be able to:

  • Discuss updates to the NCCN guidelines for breast cancer
  • Explain how these updates will impact management of breast cancer care

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the evaluation form.  A statement of credit will be electronically generated once you complete the evaluation form.  To receive credit, this activity must be completed no later than May 14, 2008.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category
1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 0.8 contact hours.  National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date:  May 14, 2007
Expiration date:  May 14, 2008

Commercial Support

Distribution supported by educational grants from AstraZeneca Pharmaceuticals LP, Abraxis Bioscience, Inc., and Genentech, Inc.